Health Economics›Leiomyosarcoma›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Leiomyosarcoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #06	—	R 307 423	28d	3.7 mo	—	5	R 1 537 113 PFS proxy	1
Eribulin monotherapy Variant #01	—	R 24 243	21d	—	12.7 mo	—	—	1
Docetaxel and Gemcitabine Variant #01	—	R 4 912	21d	~6.2 mo	—	~9	~R 44 207 PFS proxy · indirect	1
Dacarbazine and Gemcitabine Variant #01	—	R 3 790	14d	—	16.8 mo	—	—	1
Dacarbazine monotherapy Variant #01	—	R 2 094	21d	—	13.1 mo	—	—	2
Trabectedin monotherapy N/A - secondary systemic drug	—	R 109	28d	—	13.7 mo	—	—	1

6 of 6 regimens shown